8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): May 7, 2012

CORE LABORATORIES N.V.

(Exact name of registrant as specified in its charter)

001-14273

(Commission File Number)

The Netherlands	Not Applicable
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
Herengracht 424
1017 BZ Amsterdam
The Netherlands	Not Applicable
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (31-20) 420-3191

Check the appropriate below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Item 8.01 Other Events

On May 7, 2012, Core Laboratories N.V. issued a press release announcing its prospectus to dual-list its shares on NYSE Euronext in Amsterdam has been approved by the Netherlands Authority for the Financial Markets. In connection with this dual-listing, Core Lab will not be issuing any new shares. The listing on NYSE Euronext Amsterdam will be effective on the morning of Wednesday, 16 May 2012, under the symbol “CLB.”

The full text of the press release is set forth in Exhibit 99.1 attached hereto.

The information in this Report and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly stated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d)    Exhibits

99.1 Press release issued on May 7, 2012*

* This exhibit is intended to be furnished and shall not be deemed "filed" for purposes of the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Core Laboratories N.V.
Dated: May 7, 2012	By	/s/ Richard L. Bergmark
		Richard L. Bergmark
		Chief Financial Officer

CORE LABORATORIES N.V.

EXHIBIT INDEX TO FORM 8-K

EXHIBIT NO.	ITEM
99.1	Press release issued on May 7, 2012 *

* This exhibit is intended to be furnished and shall not be deemed "filed" for purposes of the Exchange Act.

EX-99.1

FOR IMMEDIATE RELEASE

For more information, contact:

Richard L. Bergmark, + 1 713 328 2101

Fax: +1 713 328 2151

CORE LAB ANNOUNCES APPROVAL OF PROSPECTUS FOR DUAL-LISTING OF COMPANY SHARES ON NYSE EURONEXT IN AMSTERDAM; TRADING TO COMMENCE ON 16 MAY 2012

AMSTERDAM (7 May 2012) - Core Laboratories N.V. (trading symbol: "CLB") has received approval from the Netherlands Authority for the Financial Markets (“AFM”) for its prospectus to dual-list its shares on NYSE Euronext in Amsterdam (“NYSE Euronext Amsterdam”). In connection with this dual-listing, Core Lab will not be issuing any new shares. The listing on NYSE Euronext Amsterdam will be effective on the morning of Wednesday, 16 May 2012, under the symbol “CLB” and Core Laboratories will open the trading session that day at the traditional Opening Gong Ceremony at NYSE Euronext Amsterdam signaling the start of the session. Shares of Core Laboratories will continue to trade on the New York Stock Exchange (“NYSE”) under the symbol “CLB”.

The prospectus dated 4 May 2012 is available to investors, free of charge, by request to Core Laboratories or may also be obtained in electronic form from the website of NYSE Euronext Amsterdam (https://europeanequities.nyx.com/) and the website of the AFM (www.afm.nl).

ING is acting as listing agent in respect of the dual listing on NYSE Euronext Amsterdam.

Core Laboratories N.V. (www.corelab.com) is a leading provider of proprietary and patented reservoir description, production enhancement, and reservoir management services used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing region in the world. Core Laboratories has been listed on the NYSE stock exchange in New York since 1998 with at the time a market capitalization of $636 million. As the Company's market capitalization has grown to just over $6 billion this year, so too has interest from prospective international institutional investors in participating in ownership of Core Lab through its publicly traded shares. Given Core's international business platform, the Company is interested in expanding investor ownership beyond the United States. European institutional investors currently hold approximately 5% of Core's outstanding shares, and the Company believes the NYSE Euronext Amsterdam dual-listing will expand Core's international investor ownership.

The Company considers NYSE Euronext Amsterdam to be a logical choice for a dual listing given its historical ties to the Netherlands, its relatively large operational footprint in the Netherlands with laboratories in Rotterdam, Vlaardingen, and Amsterdam, its client base, and the presence of several other distinctive global service providers to the oil and gas industry.

The Company's releases may include forward-looking statements regarding the future revenue, profitability, business strategies and developments of the Company made in reliance upon the safe harbor provisions of securities law. The Company's outlook is subject to various important cautionary factors, including risks

and uncertainties related to the oil and natural gas industry, business conditions, international markets, international political climates and other factors as more fully described in the Company's securities filings, both in the United States and the Netherlands. These important factors could cause the Company's factual results to differ materially from those described in these forward-looking statements. Such statements are based on current expectations of the Company's performance and are subject to a variety of factors, some of which are not under the control of the Company. Because such information is based solely on data currently available, and because it is subject to change as a result of changes in conditions over which the Company has no control or influence, such forward-looking statements should not be viewed as assurance regarding the Company's future performance. The Company undertakes no obligation to publicly update any forward looking statement to reflect events or circumstances that may arise after the date of a press release.

# # # #